CINECA IRIS Institutional Research Information System

ALBERA, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.274
EU - Europa 3.427
AS - Asia 1.776
SA - Sud America 183
OC - Oceania 160
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 9
Totale 10.863
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.068
CN - Cina 914
IT - Italia 752
GB - Regno Unito 457
IE - Irlanda 414
FR - Francia 339
SE - Svezia 312
DE - Germania 245
FI - Finlandia 213
JP - Giappone 179
CA - Canada 176
KR - Corea 169
UA - Ucraina 158
AU - Australia 129
BR - Brasile 123
IN - India 108
VN - Vietnam 103
TR - Turchia 95
ES - Italia 80
NL - Olanda 77
PL - Polonia 66
BE - Belgio 59
PT - Portogallo 48
CH - Svizzera 38
TW - Taiwan 35
NZ - Nuova Zelanda 29
AT - Austria 26
HK - Hong Kong 24
SG - Singapore 24
DK - Danimarca 23
MX - Messico 22
PK - Pakistan 22
RO - Romania 21
RU - Federazione Russa 20
ID - Indonesia 17
IL - Israele 17
TH - Thailandia 17
AR - Argentina 16
GR - Grecia 16
CO - Colombia 14
MY - Malesia 14
NO - Norvegia 14
PE - Perù 13
CL - Cile 11
IR - Iran 11
ZA - Sudafrica 11
HU - Ungheria 10
EU - Europa 9
PH - Filippine 9
EG - Egitto 7
LT - Lituania 7
CZ - Repubblica Ceca 6
BG - Bulgaria 5
BY - Bielorussia 5
HR - Croazia 5
PR - Porto Rico 5
MU - Mauritius 4
SA - Arabia Saudita 4
SK - Slovacchia (Repubblica Slovacca) 4
BD - Bangladesh 3
LB - Libano 3
TN - Tunisia 3
UY - Uruguay 3
CI - Costa d'Avorio 2
CR - Costa Rica 2
EC - Ecuador 2
FJ - Figi 2
LU - Lussemburgo 2
LV - Lettonia 2
MN - Mongolia 2
SI - Slovenia 2
GH - Ghana 1
GT - Guatemala 1
IQ - Iraq 1
LK - Sri Lanka 1
MA - Marocco 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
QA - Qatar 1
RE - Reunion 1
RW - Ruanda 1
SC - Seychelles 1
SN - Senegal 1
UG - Uganda 1
UZ - Uzbekistan 1
Totale 10.863
Salva come PNG Salva come JPEG
Città #
Houston 956
Beijing 486
Chandler 416
Dublin 393
Fairfield 286
Ashburn 207
Hangzhou 190
Redwood City 188
Wilmington 172
Seattle 135
Villeurbanne 134
Woodbridge 130
Medford 128
Torino 123
Ann Arbor 121
Princeton 114
Cambridge 90
Pisa 84
Jacksonville 77
Nyköping 74
Milan 72
Dong Ket 71
Dearborn 62
Duncan 57
Warsaw 55
Tokyo 50
Boston 48
London 48
Turin 46
Shanghai 37
Boardman 34
Ottawa 29
Toronto 28
Washington 27
New York 26
Istanbul 25
Norwalk 22
Verona 22
Paris 21
Seoul 21
Lachine 20
San Diego 20
Vienna 18
Singapore 17
Sydney 17
Taipei 17
Brussels 16
Nanjing 16
Southend 16
Guangzhou 15
Menlo Park 15
Mountain View 15
Phoenix 15
São Paulo 15
Ankara 14
Barcelona 13
Lima 13
Los Angeles 13
Seongnam 13
Auckland 12
Chicago 12
Hobart 12
Québec 12
Chengdu 11
Falls Church 11
Fremont 11
Mumbai 11
New Delhi 11
Rotterdam 11
Silver Spring 11
Atlanta 10
Bangkok 10
Denver 10
Hefei 10
Madrid 10
Nutley 10
Pittsburgh 10
San Jose 10
Zurich 10
Detroit 9
Frankfurt am Main 9
Helsinki 9
Jakarta 9
Mannheim 9
Porto 9
Rome 9
Athens 8
Auburn Hills 8
Delhi 8
Napoli 8
Oxnard 8
Padova 8
Philadelphia 8
Plymouth 8
Pune 8
Rochester 8
Santiago 8
Amsterdam 7
Baltimore 7
Brisbane 7
Totale 5.990
Salva come PNG Salva come JPEG
Nome #
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. 2.622
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. 804
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. 556
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. 465
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. 376
Documento AIPO-SIMeR sulla fibrosi polmonare idiopatica 254
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning. 242
Activated and memory alveolar T-lymphocytes in idiopathic eosinophilic pneumonia. 163
Relationship between circulating immune complexes, serum interferon and clinical features in sarcoidosis. 162
Eosinophils in eosinophilic pneumonia. 138
Evaluation of a novel tuberculosis complex-specific 34 kDa protein in the serological diagnosis of tuberculosis. 135
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial 127
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. 122
Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers. 121
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. 110
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points 107
Tachykinin activation of human alveolar macrophages in tobacco-smoke and in sarcoidosis: a phenotypical and functional study 104
Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report. 102
Human renal angiomyolipoma cells of male and female origin can migrate and are influnced by microenvironmental factors 101
The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report 100
null 96
Risultati iniziali e prospettive future del Registro Piemontese delle Cardiopatie Congenite dell'Adulto 94
Adenosine deaminase activity and fibronectin levels in bronchoalveolar lavage fluid in sarcoidosis and tuberculosis. 91
Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier 89
The clinical use of BAL in patients with pulmonary infections. 84
Corso di malattie dell'apparato respiratorio 83
First report of the Italian register for diffuse infiltrative lung disorders(RIPID). 82
Clinical guidelines and indications for bronchoalveolar lavage (BAL): pulmonary malignancies. 82
Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide. 79
Alveolar inflammation in pulmonary sarcoidosis: cells and mediators. 77
[Alveolar macrophage subpopulations and circulating monocytes. Immunophenotypic study in healthy non-smokers] 76
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial 75
Cellular and humoral cytomegalovirus immunity changes in one-year combined prophylaxis after lung transplantation: suggestions from and for clinical practice 75
Tumor/Stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis 73
Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule. 72
[Evaluation of leukocyte migration inhibition (LIF) in patients with carcinoma of the lung before and after the use of levamisole in vitro] 70
Awake or intubated surgery in diagnosis of interstitial lung diseases? A prospective study 70
Lymphocyte subpopulations analysis in pleural fluid and peripheral blood in patients with lymphocytic pleural effusions. 69
[Diagnosis of tuberculosis today] 69
Three-dimensional demonstration of systemic blood supply to normal left basal segments 67
[In vitro lymphocyte immunoreactivity in sarcoidosis patients. Stimulation with Kveim antigens] 66
Mediastinal pulmonary sarcoidosis: clinical study of 87 cases 65
[Sarcoidosis] 64
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) 64
Fibronectin levels in bronchoalveolar lavage fluid: a possible marker of sarcoidosis activity. 64
Analysis of survival in lung transplantation: Simple diagnostic tests in a new "SELeCT" Score used as prognostic tool. Results from a single center cohort study 62
Sarcoid activity markers. 60
Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. 60
Broncholaveolar Lavage in Sarcoidosis 59
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials 58
Evaluation of immunomodulating effects of inhaled bacterial polyribosomal-Klebsiella pneumoniae proteoglycans complex on bronchoalveolar immune system in chronic bronchitis. 57
Alveolar immune mediators in HIV-related pneumonia. Different role of IL-2 and IL-1 in inducing lung damage. 57
Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality? 57
Fibrosi Polmonare 54
6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): Confirmation of the minimal clinically important difference (MCID) 54
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. 53
First rigid bronchoscopy in COVID-19 pneumonia to treat a rare endobronchial tumor during extracorporeal membrane oxygenation 53
Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study. 52
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 52
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. 50
Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis 49
Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. 49
Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives 47
Alveolar and circulating CD8+ lymphocyte subsets in pulmonary sarcoidosis 46
Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA 46
Uno studio placebo-controllo sull’uso dell’interferon gamma-1b in pazienti con fibrosi polmonare idiopatica Commento editoriale da N Engl J Med 2004;350:125-33 A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis RAGHU G, BROWN KK, BRADFORD WZ, STARKO K, NOBLE PW, SCHWARTZ DA, KING TE FOR THE IDIOPATHIC PULMONARY FIBROSIS STUDY GROUP 46
Think before: a guide to early diagnosis of pulmonary hypertension in patients with connective tissue diseases and vice versa. 45
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis 44
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. 43
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials 42
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. 42
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications 40
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. 40
Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes 40
Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. 39
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) 39
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. 38
SARS-CoV-2 Detection on Bronchoalveolar Lavage: An Italian Multicenter experience 38
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials 37
Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients 35
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 35
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial 35
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 35
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) 32
Where do we stand with IPF treatment? 32
Riociguat for the treatment of pulmonary arterial hypertension. 32
Repopulation of human pulmonary epithelium by bone marrow cells: a potential means to promote repair 32
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis 31
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement 31
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis 30
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study 30
Progressive fibrosing interstitial lung diseases: A current perspective 30
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial 29
null 29
Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85) 29
Circulating biomarkers in pulmonary arterial hypertension: update and future direction. 28
Mode of Death in Patients with Pulmonary Arterial Hypertension 27
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 26
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma 26
Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. 26
Totale 11.095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.755
article - articoli 0
book - libri 0
conference - conferenze 708
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.463
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019480 0 0 0 0 0 0 0 0 0 110 249 121
2019/20202.256 93 76 108 199 195 812 186 118 145 131 122 71
2020/20211.363 103 66 124 93 108 109 100 93 150 103 105 209
2021/20221.360 85 89 100 103 80 70 67 103 83 97 225 258
2022/20231.808 163 100 64 168 197 436 185 107 166 39 99 84
2023/2024822 118 144 85 63 85 98 57 80 22 70 0 0
Totale 11.375